Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease.

Autor: Rodrigues Albuquerque E; Laboratory of Preclinical Research of Natural Products, Post Graduate Program in Animal Science with Emphasis on Bioactive Products, Universidade Paranaense, Umuarama, Brazil., Ratti da Silva G; Laboratory of Preclinical Research of Natural Products, Post Graduate Program in Animal Science with Emphasis on Bioactive Products, Universidade Paranaense, Umuarama, Brazil., de Abreu Braga F; Laboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil., Pelegrini Silva E; Laboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil., Sposito Negrini K; Laboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil., Rodrigues Fracasso JA; School of Dentistry, São Paulo State University, Araçatuba, Brazil., Pires Guarnier L; Department of Genetic, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil., Jacomassi E; Laboratory of Preclinical Research of Natural Products, Post Graduate Program in Medicinal Plants and Phytotherapeutics in Basic Attention, Paranaense University, Umuarama, Brazil., Ribeiro-Paes JT; Department of Biotechnology, São Paulo State University, Assis, São Paulo, Brazil., da Silva Gomes R; Department of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota 58102, USA., Gasparotto Junior A; Laboratory of Cardiovascular Pharmacology, Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Brazil., Lívero FADR; Laboratory of Preclinical Research of Natural Products, Paranaense University, Umuarama, Brazil.; Laboratory of Cardiometabolic Pharmacology, Federal University of Paraná, Curitiba, Brazil.
Jazyk: angličtina
Zdroj: Evidence-based complementary and alternative medicine : eCAM [Evid Based Complement Alternat Med] 2023 Nov 09; Vol. 2023, pp. 8840427. Date of Electronic Publication: 2023 Nov 09 (Print Publication: 2023).
DOI: 10.1155/2023/8840427
Abstrakt: Metabolic-associated fatty liver disease (MAFLD) is a complex condition characterized by steatosis and metabolic disturbances. Risk factors such as diabetes, cigarette smoking, and dyslipidaemia contribute to its development and progression. Effective and safe therapies for MAFLD are urgently needed. Pereskia grandifolia has shown potential as an alternative treatment, but its effectiveness against liver disease remains unexplored. This research aims to determine the hepatoprotective properties of P. grandifolia using a model of MAFLD. The study was carried out through various phases to assess the safety and efficacy of the ethanol-soluble fraction of P. grandifolia . Initially, an in vitro assay was performed to assess cell viability. This was followed by an acute toxicity test conducted in rats to determine the safety profile of the extract. Subsequently, the anti-inflammatory properties of P. grandifolia were examined in macrophages. For the MAFLD study, diabetic Wistar rats were made diabetic and exposed to a high fat diet and cigarette smoke, for 4 weeks. During the last 2 weeks, the rats were orally given either the vehicle (negative control group; C-), P. grandifolia (30, 100, and 300 mg/kg), or insulin in addition to simvastatin. A basal group of rats not exposed to these risk factors was also assessed. Blood samples were collected to measure cholesterol, triglycerides, glucose, ALT, and AST levels. Liver was assessed for lipid and oxidative markers, and liver histopathology was examined. P. grandifolia showed no signs of toxicity. It demonstrated anti-inflammatory effects by inhibiting phagocytosis and macrophage spreading. The MAFLD model induced liver abnormalities, including increased AST, ALT, disrupted lipid profile, oxidative stress, and significant hepatic damage. However, P. grandifolia effectively reversed these changes, highlighting its potential as a therapeutic agent. These findings emphasize the significance of P. grandifolia in mitigating hepatic consequences associated with various risk factors.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2023 Edilson Rodrigues Albuquerque et al.)
Databáze: MEDLINE
Externí odkaz: